Pluristem Therapeutics makes appointment
This article was originally published in Scrip
Executive Summary
Pluristem Therapeutics, a US biotherapeutics company commercialising non-personalised cell therapy products for the treatment of several degenerative, ischaemic and autoimmune disorders, has named Chaya Mazouz clinical operations director. Ms Mazouz previously served as clinical operations director for the biopharmaceutical company Medgenics.